Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792170 | 0.84 | F2 (0.61) | F2SMN1; SMN2IMPDH2 | |
| SCHEMBL6203738 | 0.82 | F2 (0.62) | F2TSHRSMN1; SMN2 | |
| SCHEMBL30105384 | 0.79 | LOXL2 (0.60) | F2 | |
| SCHEMBL3193871 | 0.79 | LOXL2 (0.60) | F2 | |
| SCHEMBL6585933 | 0.79 | F2 (0.58) | F2SMN1; SMN2IMPDH2MAOAMAOB | |
| SCHEMBL6617237 | 0.79 | F2 (0.62) | F2SMN1; SMN2IMPDH2 | |
| SCHEMBL28178529 | 0.79 | F2 (0.58) | F2SMN1; SMN2IMPDH2 | |
| SCHEMBL6824873 | 0.79 | LOXL2 (0.60) | F2SMN1; SMN2 | |
| SCHEMBL977626 | 0.78 | F2 (0.70) | F2PPARGTSHRSMN1; SMN2 | |
| SCHEMBL20143884 | 0.78 | AHR (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |